{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:49:58Z","timestamp":1791834598173,"version":"4.3.4"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Metabolism"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.molmet.2026.102452","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:23:30Z","timestamp":1791041010000},"page":"102452","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Nisotirostide (LY3457263), a novel NPY2 receptor agonist for type 2 diabetes and obesity: From discovery to clinical proof of concept"],"prefix":"10.1016","volume":"114","author":[{"given":"Daniel A.","family":"Briere","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer K.","family":"Leohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helle","family":"Linnebjerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avinash","family":"Muppidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Antonellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Antonellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd M.","family":"Suter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Smith LaBell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mridula","family":"Dogra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamer","family":"Coskun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Alsina-Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieren J.","family":"Mather","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.molmet.2026.102452_bib1","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00125-025-06581-6","article-title":"Pharmacological therapies for type 2 diabetes: future approaches","volume":"69","author":"Bailey","year":"2026","journal-title":"Diabetologia"},{"issue":"11","key":"10.1016\/j.molmet.2026.102452_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25116218","article-title":"New molecules in type 2 diabetes: advancements, challenges and future directions","volume":"25","author":"Chatzianagnostou","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.molmet.2026.102452_bib3","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ncp.11279","article-title":"Use of glucagon-like peptide-1 receptor agonists and incretin mimetics for type 2 diabetes and obesity: a narrative review","volume":"40","author":"Zupec","year":"2025","journal-title":"Nutr Clin Pract"},{"issue":"2\u20133","key":"10.1016\/j.molmet.2026.102452_bib4","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1515\/jbcpp-2025-0031","article-title":"Incretin-based therapies: advancements, challenges, and future directions in type 2 diabetes management","volume":"36","author":"Alluri","year":"2025","journal-title":"J Basic Clin Physiol Pharmacol"},{"issue":"2","key":"10.1016\/j.molmet.2026.102452_bib5","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1007\/s12325-021-01985-3","article-title":"Individualized HbA(1c) goals, and patient awareness and attainment of goals in type 2 diabetes mellitus: a real-world multinational survey","volume":"39","author":"Lautsch","year":"2022","journal-title":"Adv Ther"},{"issue":"3","key":"10.1016\/j.molmet.2026.102452_bib6","doi-asserted-by":"crossref","DOI":"10.1530\/JOE-23-0404","article-title":"Gut hormone multi-agonists for the treatment of type 2 diabetes and obesity: advances and challenges","volume":"262","author":"Huang","year":"2024","journal-title":"J Endocrinol"},{"issue":"1","key":"10.1016\/j.molmet.2026.102452_bib7","doi-asserted-by":"crossref","first-page":"10","DOI":"10.5009\/gnl.2012.6.1.10","article-title":"Gut hormones and appetite control: a focus on PYY and GLP-1 as therapeutic targets in obesity","volume":"6","author":"De Silva","year":"2012","journal-title":"Gut Liver"},{"issue":"5","key":"10.1016\/j.molmet.2026.102452_bib8","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1381\/096089206776944959","article-title":"Peptide YY(1-36) and peptide YY(3-36): part I. Distribution, release and actions","volume":"16","author":"Ballantyne","year":"2006","journal-title":"Obes Surg"},{"issue":"8","key":"10.1016\/j.molmet.2026.102452_bib9","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1073\/pnas.79.8.2514","article-title":"Isolation and characterization of peptide YY (PYY), a candidate gut hormone that inhibits pancreatic exocrine secretion","volume":"79","author":"Tatemoto","year":"1982","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6898","key":"10.1016\/j.molmet.2026.102452_bib10","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/nature00887","article-title":"Gut hormone PYY(3-36) physiologically inhibits food intake","volume":"418","author":"Batterham","year":"2002","journal-title":"Nature"},{"issue":"11\u201312","key":"10.1016\/j.molmet.2026.102452_bib11","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1055\/s-2004-826160","article-title":"Circulation and degradation of GIP and GLP-1","volume":"36","author":"Deacon","year":"2004","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.molmet.2026.102452_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106808","article-title":"Evolution of peptide YY analogs for the management of type 2 diabetes and obesity","volume":"140","author":"Chen","year":"2023","journal-title":"Bioorg Chem"},{"issue":"4","key":"10.1016\/j.molmet.2026.102452_bib13","doi-asserted-by":"crossref","first-page":"E1062","DOI":"10.1152\/ajpendo.00450.2006","article-title":"Effects of PYY1-36 and PYY3-36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in Obese and lean subjects","volume":"292","author":"Sloth","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.molmet.2026.102452_bib14","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1749-6632.2003.tb03176.x","article-title":"The gut hormone peptide YY regulates appetite","volume":"994","author":"Batterham","year":"2003","journal-title":"Ann N Y Acad Sci"},{"issue":"10","key":"10.1016\/j.molmet.2026.102452_bib15","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1056\/NEJMoa030204","article-title":"Inhibition of food intake in obese subjects by peptide YY3-36","volume":"349","author":"Batterham","year":"2003","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.molmet.2026.102452_bib16","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s00125-013-2887-z","article-title":"Co-localisation and secretion of glucagon-like peptide 1 and peptide YY from primary cultured human L cells","volume":"56","author":"Habib","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.molmet.2026.102452_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101392","article-title":"Peptide-YY(3-36)\/glucagon-like peptide-1 combination treatment of Obese diabetic mice improves insulin sensitivity associated with recovered pancreatic \u03b2-cell function and synergistic activation of discrete hypothalamic and brainstem neuronal circuitries","volume":"55","author":"Boland","year":"2022","journal-title":"Mol Metabol"},{"issue":"791","key":"10.1016\/j.molmet.2026.102452_bib18","doi-asserted-by":"crossref","first-page":"eadq6392","DOI":"10.1126\/scitranslmed.adq6392","article-title":"Variant screening of PYY(3-36) leads to potent long-acting PYY analogs with superior Y(2) receptor selectivity","volume":"17","author":"Ostergaard","year":"2025","journal-title":"Sci Transl Med"},{"issue":"11","key":"10.1016\/j.molmet.2026.102452_bib19","doi-asserted-by":"crossref","first-page":"E1248","DOI":"10.1152\/ajpendo.00569.2013","article-title":"Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure, and appetite in overweight men","volume":"306","author":"Schmidt","year":"2014","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.molmet.2026.102452_bib20","doi-asserted-by":"crossref","first-page":"R866","DOI":"10.1152\/ajpregu.00394.2015","article-title":"In vivo and in vitro degradation of peptide YY3-36 to inactive peptide YY3-34 in humans","volume":"310","author":"Tor\u00e4ng","year":"2016","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.molmet.2026.102452_bib21","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.2147\/DDDT.S506957","article-title":"A comprehensive review on the pharmacokinetics and drug-drug interactions of approved GLP-1 receptor agonists and a dual GLP-1\/GIP receptor agonist","volume":"19","author":"Min","year":"2025","journal-title":"Drug Des Dev Ther"},{"issue":"4","key":"10.1016\/j.molmet.2026.102452_bib22","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S2213-8587(14)70014-2","article-title":"GLP-1 receptor agonists: why is once weekly inferior to once daily?","volume":"2","author":"Garber","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"17","key":"10.1016\/j.molmet.2026.102452_bib23","doi-asserted-by":"crossref","first-page":"9660","DOI":"10.1021\/acs.jmedchem.0c00740","article-title":"Engineering of a potent, long-acting NPY2R agonist for combination with a GLP-1R agonist as a multi-hormonal treatment for obesity","volume":"63","author":"Lear","year":"2020","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.molmet.2026.102452_bib24","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1021\/acs.jmedchem.0c01783","article-title":"Design and evaluation of peptide dual-agonists of GLP-1 and NPY2 receptors for glucoregulation and weight loss with mitigated nausea and emesis","volume":"64","author":"Milliken","year":"2021","journal-title":"J Med Chem"},{"issue":"20","key":"10.1016\/j.molmet.2026.102452_bib25","doi-asserted-by":"crossref","first-page":"14201","DOI":"10.1021\/acs.jmedchem.2c01385","article-title":"Design of xenopus GLP-1-Based long-acting dual GLP-1\/Y(2) receptor agonists","volume":"65","author":"Yang","year":"2022","journal-title":"J Med Chem"},{"issue":"8","key":"10.1016\/j.molmet.2026.102452_bib26","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/oby.24329","article-title":"Long-acting PYY(3) (-36) analogue with semaglutide for obesity: from preclinical assessment through randomized clinical studies","volume":"33","author":"Wulff","year":"2025","journal-title":"Obesity"},{"key":"10.1016\/j.molmet.2026.102452_bib27","series-title":"Peptide YY analogs","author":"Dock","year":"2016"},{"issue":"23","key":"10.1016\/j.molmet.2026.102452_bib28","doi-asserted-by":"crossref","first-page":"10519","DOI":"10.1021\/acs.jmedchem.8b01046","article-title":"Design of Y(2) receptor selective and proteolytically stable PYY(3-36) analogues","volume":"61","author":"Ostergaard","year":"2018","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.molmet.2026.102452_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-00654-3","article-title":"The effect of fatty diacid acylation of human PYY(3-36) on Y(2) receptor potency and half-life in minipigs","volume":"11","author":"Ostergaard","year":"2021","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.molmet.2026.102452_bib30","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/dom.15984","article-title":"A randomized phase I study of BI 1820237, a novel neuropeptide Y receptor type 2 agonist, alone or in combination with low-dose liraglutide in otherwise healthy men with overweight or obesity","volume":"27","author":"Beetz","year":"2025","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.molmet.2026.102452_bib31","series-title":"Protein tyrosine-tyrosine analogs and methods of using the same","author":"Briere","year":"2023"},{"key":"10.1016\/j.molmet.2026.102452_bib32","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","article-title":"The toxicity of poisons applied jointly","volume":"26","author":"Bliss","year":"1939","journal-title":"Ann Appl Biol"},{"issue":"1","key":"10.1016\/j.molmet.2026.102452_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/clinem\/dgae719","article-title":"Clinical consequences of delayed gastric emptying with GLP-1 receptor agonists and tirzepatide","volume":"110","author":"Jalleh","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.molmet.2026.102452_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2025.102205","article-title":"Novel NPY2R agonist BI 1820237 provides synergistic anti-obesity efficacy when combined with the GCGR\/GLP-1R dual agonist survodutide","volume":"99","author":"Augustin","year":"2025","journal-title":"Mol Metabol"},{"issue":"7","key":"10.1016\/j.molmet.2026.102452_bib35","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1111\/dom.14358","article-title":"Safety and efficacy of an extended-release peptide YY analogue for obesity: a randomized, placebo-controlled, phase 1 trial","volume":"23","author":"Tan","year":"2021","journal-title":"Diabetes Obes Metabol"}],"container-title":["Molecular Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212877826001365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212877826001365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:28:30Z","timestamp":1791833310000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212877826001365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":35,"alternative-id":["S2212877826001365"],"URL":"https:\/\/doi.org\/10.1016\/j.molmet.2026.102452","relation":{},"ISSN":["2212-8778"],"issn-type":[{"value":"2212-8778","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nisotirostide (LY3457263), a novel NPY2 receptor agonist for type 2 diabetes and obesity: From discovery to clinical proof of concept","name":"articletitle","label":"Article Title"},{"value":"Molecular Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmet.2026.102452","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"102452"}}